- MSDI +38%.
- DRYS +32% on announcement of delivery of Newcastlemax vessel.
- CLSN +28% on completion of OVATION study and provides update on advanced stage III and IV Ovarian Cancer.
- MTBC +24% on acquisition of a Washington-based revenue cycle management company's client accounts and related business assets.
- MORE +22% on being sold for $12/share.
- FCEL +10% on renewable power project.
- BLFS +8% on modifying its existing credit facilities.
- OPXA +8%.
- IMNP +7% on publication of clinical trial results on the use of Ceplene (histamine dihydrochloride) for relapse prevention in patients with acute myeloid leukemia.
- PRAN +7%.
- ABIL +5%.